MSB Named Global Technology Leader In Cell Therapy Industry
Filed with ASX · · 2 pages · English
Earlier from Mesoblast
- Response to ASX Aware Letter Query
- Mesoblast Provides Corporate Update and Q1 Financial Results
- RA Phase 2 Trial Results Presented At ACR Annual Meeting
- End-Stage Heart Failure Trial Completes Enrollment
- Mesoblast Corporate Updates at Healthcare Conferences
Later from Mesoblast
- Mesoblast Grants TiGenix License For Treatment of Fistulae
- Mesoblasts P3 GVHD Trial Completes Enrollment
- Mesoblast Receives RMAT For LVAD Heart Failure Patients
- Appendix 3B with prospectus
- Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast